Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 12 de 12
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Haemophilia ; 13(4): 387-90, 2007 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-17610553

RESUMEN

A study of major joint outcomes, specifically range of motion and synovitis, was conducted with data from a subset of adolescents enrolled in the prospective Hemophilia Growth and Development Study (HGDS). Clinical observations were carried out over a 7-year period from 1989 to 1996. A secondary aim was to gain insight into factors that might influence decisions regarding maintaining or discontinuing prophylaxis during early adulthood. Twenty-nine participants (median age 17.4 at entry) were included. Median follow-up was 7 years (range: 4.8-7.7). Range of motion (ROM) and synovitis in six major joints (knees, elbows and ankles), were evaluated by physical examination every 6-12 months. At the baseline observation, 73.6% of joints showed no ROM abnormalities or synovitis, and all joints were normal in 11 patients. Of the 11 participants, 54.5% developed abnormalities and 28.1% of normal joints at baseline became abnormal during the follow-up. Ankles were the most severely affected and had persistent progression during late adolescence and adulthood. Elbows and knees did not show progression after the first few years of the follow-up. The progression of haemophilic arthropathy in adolescents and young adults varies from individual to individual and also in the site of affected joints. In view of this, the decision regarding discontinuation of prophylaxis in patients with haemophilia should be individualized.


Asunto(s)
Factores de Coagulación Sanguínea/uso terapéutico , Hemofilia A/complicaciones , Artropatías/etiología , Sinovitis/psicología , Adolescente , Adulto , Niño , Humanos , Artropatías/prevención & control , Estudios Longitudinales , Estudios Prospectivos , Rango del Movimiento Articular/fisiología , Sinovitis/prevención & control , Resultado del Tratamiento
2.
Haemophilia ; 10(3): 295-8, 2004 May.
Artículo en Inglés | MEDLINE | ID: mdl-15086331

RESUMEN

Use of recombinant factor VIIa (rFVIIa, NovoSeven in patients with congenital FVII deficiency has been reported for the prophylactic management of surgical bleeding and for the treatment of acute bleeding episodes. Because of its short half-life, the use of rFVIIa on a regular prophylactic regimen has not been routinely adopted. In this report, we describe our successful experience with rFVIIa prophylaxis in preventing recurrent target joint bleeding in a severely FVII-deficient adolescent.


Asunto(s)
Deficiencia del Factor VII/prevención & control , Factor VII/uso terapéutico , Proteínas Recombinantes/uso terapéutico , Adolescente , Deficiencia del Factor VII/congénito , Factor VIIa , Hemartrosis/etiología , Hemartrosis/prevención & control , Humanos , Masculino
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...